Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.83 +0.34 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
40 41 Next >
News headline image
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness ↗
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Down 2.5%; IGM Biosciences Shares Jump ↗
U.S. stocks traded higher midway through trading, with the Dow jumping over 250 points on Tuesday. 
Via Benzinga
News headline image
36 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: IGMS) shares jumped 49.8% to $22.46. Sanofi SA (... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Higher; McCormick Profit Beats Estimates ↗
U.S. stocks opened on a strong note on Tuesday, with the Dow jumping around 350 points this morning. 
Via Benzinga
News headline image
IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi ↗
Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against  
Via Benzinga
News headline image
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
20 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration with Sanofi (NASDAQ: SNY). Guardforce AI Co.,... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Higher Ahead Of Earnings, Fed Speakers ↗
Pre-open movers 
Via Benzinga
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
News headline image
Regeneron-Sanofi's Dupixent Significantly Improved Signs, Symptoms In Chronic Itchy Skin Disease ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) have presented  
Via Benzinga
News headline image
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC ↗
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection. 
Via Benzinga
News headline image
Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market ↗
After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock. The Moderna Analyst: BofA... 
Via Benzinga
News headline image
Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC ↗
U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases. 
Via Benzinga
News headline image
Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Up to 60,000 people in the US with a rare genetic kidney... 
Via Benzinga
News headline image
Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC ↗
The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren& 
Via Benzinga
News headline image
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
From Seagen Inc.
Via Business Wire
News headline image
Why Sanofi Shares Are Trading Lower Today ↗
Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in... 
Via Benzinga
News headline image
JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474 ↗
JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says... 
Via Benzinga
News headline image
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care ↗
The IBD/TIPP Poll shows Covid has fallen among Americans' priorities. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... 
Via Benzinga
News headline image
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients ↗
Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001)... 
Via Benzinga
News headline image
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC ↗
BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116... 
Via Benzinga
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
Via AB Newswire
News headline image
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi ↗
Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in... 
Via Talk Markets
News headline image
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants ↗
AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory... 
Via Benzinga
News headline image
36 Stocks To Watch After Biden's First State of The Union Address ↗
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
News headline image
Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact ↗
Sanofi SA (NASDAQ: SNY) has signed a collaboration with Adagene Inc (NASDAQ: ADAG) to advance two preclinical immuno-oncology candidates and an option to... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.